Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

Paolo Manca; Marco Russano; Francesco Pantano; Giuseppe Tonini; Daniele Santini

doi:10.18632/oncotarget.17607

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

Paolo Manca, Marco Russano _, Francesco Pantano, Giuseppe Tonini and Daniele Santini

PDF | HTML | How to cite

Oncotarget. 2017; 8:59986-59990. https://doi.org/10.18632/oncotarget.17607

Metrics: PDF 1426 views | HTML 2105 views | ?

Abstract

Paolo Manca1, Marco Russano1, Francesco Pantano1, Giuseppe Tonini1 and Daniele Santini1

1 Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy

Correspondence to:

Marco Russano, email:

Keywords: afatinib resistance, EGFR-TKI resistance, EGFR inhibitor resistance, small cell lung cancer switch, tumor switch

Received: March 20, 2017 Accepted:April 17, 2017 Published: May 04, 2017

Abstract

We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17607

Publication Alerts

Case Reports:

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

Abstract